01. Executive Summary 02. Introduction 03. Market Coverage Market Overview Key Offerings 04. Market Landscape 04.1 Market Size 04.2 Market Forecast 04.3 Market Segmentation 04.4 Five Forces Analysis 05. Geographical Segmentation 06. Key Leading Countries US Germany Japan 07. Rate of Incidence and Prevalence 08. Vendor Landscape 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and Their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Key Vendor Analysis 15.1 AVEO Pharmaceuticals Inc. Business Overview Key Information SWOT Analysis 15.2 Bayer AG Business Overview Key Information SWOT Analysis 15.3 GlaxoSmithKline plc Business Overview Key Information SWOT Analysis 15.4 Hoffmann-La Roche Ltd. Business Overview Key Information SWOT Analysis 15.5 Novartis AG Business Overview Key Information SWOT Analysis 15.6 Pfizer Inc. Business Overview Key Information SWOT Analysis 16. Other Reports in this Series List of Exhibits Exhibit 1: Global Kidney Cancer Drugs Market 2012–2016 (US$ billion) Exhibit 2: Kidney Cancer by Category Segmentation Exhibit 3: Global Kidney Cancer Drugs Market by Category Segmentation 2012 Exhibit 4: Global Kidney Cancer Drugs Market by Geographical Segmentation 2012 Exhibit 5: Global Kidney Cancer Drugs Market by Vendor Segmentation 2012 Exhibit 6: Business Segmentation of AVEO Pharmaceuticals Inc. Exhibit 7: Business Segmentation of Bayer AG Exhibit 8: Business Segmentation of GlaxoSmithKline plc Exhibit 9: Business Segmentation of Hoffmann-La Roche Ltd. Exhibit 10: Business Segmentation of Novartis AG Exhibit 11: Business Segmentation of Pfizer Inc.

AVEO Pharmaceuticals Inc., Bayer AG, GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AstraZeneca plc, Onyx Pharmaceuticals Inc., Merck Serono S.A., and WILEX AG